The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...
Add Yahoo as a preferred source to see more of our stories on Google. A major international trial finds that adding niraparib to standard prostate cancer therapy delays disease progression. (CREDIT: ...
Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...
Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.
In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results